Bauer et al developed equations for predicting outcomes prior to radical prostatectomy in men with prostate cancer. The authors are from Walter Reed Medical Center and the Uniformed Services University of Health Sciences.
Patient selection: prostate cancer with clinical Stage 1 or 2
Parameters:
(1) sigmoidal transformation for the PSA (see Chapter 16)
(2) maximum preoperative Gleason score (worst)
(3) clinical tumor stage
(4) race
Parameter |
Finding |
Points |
tumor stage |
not that stage |
0 |
|
that stage |
1 |
race |
Black (Afro-American) |
1 |
|
other (Asian, Hispanic, White) |
0 |
X for recurrence risk =
= (0.47 * (points for race)) + (0.14 * (sigmoidal transformation of the PSA)) + (0.13 * (maximum Gleason score)) + (1.03 if Stage 1c) + (1.55 if Stage 2b or 2c)
risk score for recurrence =
= EXP(X)
Risk Score for Recurrence |
Risk for Recurrence |
< 8.0 |
low |
8.0 to 40.0 |
intermediate |
> 40.0 |
high |
Y for extracapsular extension at surgery =
= (0.18 * (points for race)) + (0.15 * (sigmoidal transformation of the PSA)) + (0.31 * (maximum Gleason score)) + (0.16 if Stage 1c) + (0.38 if Stage 2b or 2c) - 2.47
probability of extracapsular extension =
= 1 / (1 + EXP((-1) * Y))
Probability of Extracapsular Extension |
Risk for Extracapsular Extension |
< 0.43 |
low |
0.43 to 0.77 |
intermediate |
> 0.77 |
high |
NOTE: An online version of the algorithm is available at the Center for Prostate Disease Research (www.cpdr.org). In this version clinical stage T3 is included with T2b or T2c).
Specialty: Hematology Oncology, Surgery, general, Urology
ICD-10: ,